Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.39 |
| ▸ | IL1B | P01584 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22409315 | 1.00 | ARG1 (0.39) | ARG1IL1BP2RX7 | |
| SCHEMBL18461546 | 0.76 | HTR1A (0.38) | ARG1 | |
| SCHEMBL18424778 | 0.76 | HTR1A (0.38) | ARG1 | |
| SCHEMBL22409346 | 0.75 | ARG1 (0.39) | ARG1 | |
| SCHEMBL8557435 | 0.75 | GAA (0.42) | ARG1 | |
| SCHEMBL8563302 | 0.75 | ARG1 (0.39) | ARG1 | |
| Hydrochloric Acid SCHEMBL8563521 | 0.74 | ARG1 (0.38) | ARG1 | |
| SCHEMBL18461756 | 0.66 | HTR1A (0.39) | ARG1IL1BP2RX7 | |
| SCHEMBL18425141 | 0.66 | HTR1A (0.39) | ARG1IL1BP2RX7 | |
| SCHEMBL3440569 | 0.66 | JAK2 (0.39) | ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ARG1 65/4885IL1B 4398/4885P2RX7 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.